Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Non-Current Debt (2016 - 2025)

Historic Non-Current Debt for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to $70.1 million.

  • Adma Biologics' Non-Current Debt fell 3083.32% to $70.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.1 million, marking a year-over-year decrease of 3083.32%. This contributed to the annual value of $72.3 million for FY2024, which is 4460.92% down from last year.
  • According to the latest figures from Q3 2025, Adma Biologics' Non-Current Debt is $70.1 million, which was down 3083.32% from $73.4 million recorded in Q2 2025.
  • Adma Biologics' Non-Current Debt's 5-year high stood at $144.3 million during Q1 2023, with a 5-year trough of $70.1 million in Q3 2025.
  • In the last 5 years, Adma Biologics' Non-Current Debt had a median value of $130.6 million in 2023 and averaged $113.0 million.
  • Per our database at Business Quant, Adma Biologics' Non-Current Debt skyrocketed by 5056.25% in 2022 and then plummeted by 4460.92% in 2024.
  • Over the past 5 years, Adma Biologics' Non-Current Debt (Quarter) stood at $94.9 million in 2021, then soared by 50.56% to $142.8 million in 2022, then decreased by 8.57% to $130.6 million in 2023, then tumbled by 44.61% to $72.3 million in 2024, then dropped by 3.11% to $70.1 million in 2025.
  • Its Non-Current Debt stands at $70.1 million for Q3 2025, versus $73.4 million for Q2 2025 and $72.5 million for Q1 2025.